<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25574" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nasopharyngeal Cancer</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sinha</surname>
            <given-names>Shreya</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winters</surname>
            <given-names>Ryan</given-names>
          </name>
          <aff>Ochsner Health System</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gajra</surname>
            <given-names>Ajeet</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shreya Sinha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ryan Winters declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ajeet Gajra declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25574.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Nasopharyngeal carcinoma is a distinct subtype of head and neck cancer. Originating in the nasopharynx, this condition presents unique characteristics that set it apart from other head and neck squamous cell carcinomas. This activity navigates through the World Health Organization's histological classification, addressing the&#x000a0;3 subtypes of nasopharyngeal carcinoma, nasopharynx anatomy, and the fossa of Rosenmulleras the primary subsite of origin. This activity aims to broaden the understanding of nasopharyngeal carcinoma, shedding light on its association with the Epstein-Barr virus and distinguishing it from oropharyngeal cancers linked to other viruses.</p>
        <p>Emphasizing the interprofessional approach, this activity underscores the collaborative role of healthcare teams in diagnosing and&#x000a0;caring for patients with nasopharyngeal carcinoma. By exploring the unique characteristics of NPC, healthcare professionals&#x000a0;are better equipped to collaborate in delivering patient-centered care and optimizing outcomes for individuals affected by this distinct form of head and neck cancer.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the distinct histologic features of nasopharyngeal carcinoma through thorough examination and diagnostic tools.</p></list-item><list-item><p>Differential nasopharyngeal carcinoma&#x000a0;from other head and neck cancers based on specific etiologic factors, geographical risk patterns, and unique disease spread characteristics.</p></list-item><list-item><p>Implement tailored treatment plans for nasopharyngeal carcinoma, emphasizing nonsurgical approaches such as radiation therapy and incorporating chemotherapy or immunotherapy based on the disease stage.</p></list-item><list-item><p>Coordinate follow-up care and surveillance strategies post-treatment, involving regular physical examinations, nasal endoscopies, and appropriate imaging to monitor disease status and manage potential long-term complications.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25574&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25574">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25574.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>The pharynx is&#x000a0;a tubular structure that connects the nose to the trachea. The upper portion of the pharynx, known as the nasopharynx,&#x000a0;is surrounded by various structures.&#x000a0;Anteriorly, the posterior choanae of the nasal cavity borders it. Posteriorly, it is enclosed by the mucosa overlying the superior pharyngeal constrictor. Laterally, it is defined by the fossae of Rosenmuller, eustachian tube orifices, and tori tubarius. Superiorly, it is constrained by the sphenoid, and inferiorly, it is connected&#x000a0;to the soft palate.</p>
        <p>Cancers arising from this area are&#x000a0;most commonly&#x000a0;squamous cell carcinoma. These cancers may&#x000a0;exhibit&#x000a0;distinctive behaviors compared to other&#x000a0;head and neck squamous cell carcinomas and have unique risk and etiologic factors. The most common&#x000a0;subsite of origin is the fossa of Rosenmuller, accounting for 50% of nasopharyngeal carcinomas.<xref ref-type="bibr" rid="article-25574.r1">[1]</xref>&#x000a0;</p>
        <p>There are distinct geographic and ethnic risk factors for nasopharyngeal carcinoma. In Asia, mainly China, there is a high&#x000a0;incidence of disease. Having Chinese ancestry is an independent risk factor regardless of residence location.<xref ref-type="bibr" rid="article-25574.r2">[2]</xref>&#x000a0;A high incidence of nasopharyngeal cancer has also been noted in those of Native Alaskan ancestry.<xref ref-type="bibr" rid="article-25574.r3">[3]</xref></p>
        <p>Most cases in areas with a high disease incidence are related to Epstein-Barr virus (EBV) infection. However, the near-ubiquity of EBV in the global population makes specific viral etiologic pathways challenging to understand.<xref ref-type="bibr" rid="article-25574.r4">[4]</xref> Viral oncogenes <italic toggle="yes">LMP-1</italic>, <italic toggle="yes">LMP-2</italic>, and <italic toggle="yes">EBNA1</italic> have been&#x000a0;demonstrated to play an important role.<xref ref-type="bibr" rid="article-25574.r5">[5]</xref> Although human papillomavirus (HPV)-related&#x000a0;nasopharyngeal cancers&#x000a0;have also been reported, no clear association has been established.</p>
        <p>The clinical behavior of&#x000a0;nasopharyngeal cancers varies depending on their histological subtype. The World Health Organization (WHO) has classified nasopharyngeal carcinoma into&#x000a0;3 subtypes based on histology. Type 1 is keratinizing squamous cell carcinoma, associated with EBV infection in around 70% to 80% of cases.<xref ref-type="bibr" rid="article-25574.r6">[6]</xref> Type 2 is differentiated nonkeratinizing carcinoma, and type 3 is undifferentiated carcinoma, the most common&#x000a0;subtype of&#x000a0;nasopharyngeal cancer.<xref ref-type="bibr" rid="article-25574.r7">[7]</xref>&#x000a0;The latter 2 types are also most responsive to treatment. Almost all cases of type 2 and type 3 are related to EBV and occur in areas where EBV is endemic.&#x000a0;Nasopharyngeal cancer&#x000a0;with basaloid features is a newer, rarer histologic category known to behave aggressively.<xref ref-type="bibr" rid="article-25574.r8">[8]</xref>&#x000a0;</p>
        <p>Treatment is determined based on stage and&#x000a0;is typically nonsurgical owing to technical reasons. Radiation therapy may be used alone for early (stage I and II) disease, while chemotherapy may be added for stage III or IV disease. Genetic markers, including some viral-related surface proteins, may also be used as targets for immunotherapy.<xref ref-type="bibr" rid="article-25574.r9">[9]</xref>&#x000a0;</p>
        <p>Over the past decade, mortality related to&#x000a0;nasopharyngeal cancers&#x000a0;has&#x000a0;seen improvement attributed&#x000a0;to early detection and advances in treatment.<xref ref-type="bibr" rid="article-25574.r10">[10]</xref><xref ref-type="bibr" rid="article-25574.r11">[11]</xref><xref ref-type="bibr" rid="article-25574.r12">[12]</xref>&#x000a0;This progress underscores the importance of ongoing research and innovations in nasopharyngeal cancer management.</p>
      </sec>
      <sec id="article-25574.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The precise etiology of nasopharyngeal carcinoma is complex and not&#x000a0;fully understood. Carcinogenesis is most likely due to hereditary genetics, environmental factors, and viral factors. In areas where EBV is not endemic, such as the US, smoking and alcohol&#x000a0;have been&#x000a0;identified&#x000a0;as&#x000a0;risk factors for nasopharyngeal carcinoma. Conversely, in EBV-endemic areas, this association does not hold.<xref ref-type="bibr" rid="article-25574.r13">[13]</xref>&#x000a0;This&#x000a0;difference is&#x000a0;reflected by WHO type 1 tumors, which are more variable in etiology and unrelated to EBV. In comparison, the association between EBV and WHO type 2 and 3 tumors is definitive.<xref ref-type="bibr" rid="article-25574.r14">[14]</xref>&#x000a0;</p>
        <p>Other risk factors include Asian ancestry, particularly Chinese ancestry, remaining an independent risk factor even outside of Asia.<xref ref-type="bibr" rid="article-25574.r15">[15]</xref>&#x000a0;This theory explains the increased nasopharyngeal carcinoma&#x000a0;risk in those of Native Alaskan ancestry, as common ancestral genetic links have been described utilizing D4h mitochondrial DNA analysis.<xref ref-type="bibr" rid="article-25574.r16">[16]</xref>&#x000a0;Dietary risk factors, such as diets high in preserved foods containing nitrosamines (particularly salted preserved fish), have also been postulated to confer additional risk of nasopharyngeal carcinoma.<xref ref-type="bibr" rid="article-25574.r17">[17]</xref>&#x000a0;</p>
        <p>Some epidemiologic studies establish family&#x000a0;clusters of&#x000a0;nasopharyngeal cancer in endemic and nonendemic areas, suggesting ancestral genetics and environmental factors likely play an etiologic role.<xref ref-type="bibr" rid="article-25574.r18">[18]</xref><xref ref-type="bibr" rid="article-25574.r19">[19]</xref>&#x000a0;In some endemic areas worldwide, circulating EBV DNA is utilized for screening and disease surveillance. High circulating levels of EBV DNA are associated with poorer treatment response and higher rates of distant metastasis and mortality.<xref ref-type="bibr" rid="article-25574.r20">[20]</xref>&#x000a0;The prognostic value of circulating EBV titers has not been extensively studied, but persistently elevated EBV titers after treatment have been described as a powerful poor prognostic factor for overall survival.<xref ref-type="bibr" rid="article-25574.r21">[21]</xref><xref ref-type="bibr" rid="article-25574.r22">[22]</xref></p>
      </sec>
      <sec id="article-25574.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>There are significant geographic variations in the epidemiology of nasopharyngeal carcinoma. In nonendemic areas,&#x000a0;such as&#x000a0;the&#x000a0;Americas and Europe,&#x000a0;nasopharyngeal cancer is rare, with less than 1 case per 100,000 people.<xref ref-type="bibr" rid="article-25574.r23">[23]</xref>&#x000a0;The incidence is much higher, reaching up to&#x000a0;21 cases per 100,000 people in&#x000a0;certain parts of China, where nasopharyngeal carcinoma accounts for 18% of all cancers.<xref ref-type="bibr" rid="article-25574.r24">[24]</xref>&#x000a0;In Asia,&#x000a0;nasopharyngeal carcinoma is a disease of middle age, with patients presenting in the 4th through 6th decades of life.<xref ref-type="bibr" rid="article-25574.r25">[25]</xref>&#x000a0;In Africa, another area with&#x000a0;endemic EBV infection, the majority of cases are&#x000a0;observed in children.<xref ref-type="bibr" rid="article-25574.r26">[26]</xref><xref ref-type="bibr" rid="article-25574.r27">[27]</xref>&#x000a0;</p>
        <p>Nonendemic areas&#x000a0;regions, such as the Americas and Europe,&#x000a0;exhibit&#x000a0;a bimodal age distribution. The first peak occurs in the late teenage years,&#x000a0;and&#x000a0;the second peak&#x000a0;appears in the&#x000a0;sixth to seventh&#x000a0;decade of life.<xref ref-type="bibr" rid="article-25574.r28">[28]</xref>&#x000a0;Gender discrepancies&#x000a0;exist&#x000a0;in the risk of developing nasopharyngeal carcinoma and in nasopharyngeal carcinoma-specific&#x000a0;mortality. Males are&#x000a0;traditionally&#x000a0;reported to have&#x000a0;a 2.75-fold higher risk of developing nasopharyngeal carcinoma and a 3.25-fold greater risk of dying from&#x000a0;nasopharyngeal carcinoma&#x000a0;compared to females.<xref ref-type="bibr" rid="article-25574.r29">[29]</xref>&#x000a0;It remains unclear&#x000a0;whether this additional risk and mortality&#x000a0;are related to differing tobacco use patterns among men and women, and&#x000a0;much of the data originates from China. In this endemic area, tobacco smoking is much more common among men than women. Some of these discrepancies have also been age-dependent, with risk and mortality nearly equivalent in those over 55 years in one Chinese study.<xref ref-type="bibr" rid="article-25574.r30">[30]</xref></p>
      </sec>
      <sec id="article-25574.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Nasopharyngeal carcinoma stands out as a distinct subtype of head and neck cancer with&#x000a0;a pathogenesis&#x000a0;that is equally&#x000a0;unique. Most&#x000a0;nasopharyngeal carcinoma cases&#x000a0;are EBV-related, and research regarding pathogenesis and malignant transformation in&#x000a0;nasopharyngeal carcinoma&#x000a0;has focused&#x000a0;on various viral gene products, along with host genetic factors that may&#x000a0;increase susceptibility to EBV infection.<xref ref-type="bibr" rid="article-25574.r31">[31]</xref></p>
        <p>In endemic areas, the majority of nasopharyngeal carcinoma tumor cells and precancerous lesions have been found to contain isolated EBV DNA, reinforcing causative association. Additionally,&#x000a0;a strong correlation exists with human leukocyte antigen (HLA) mutations that&#x000a0;increase susceptibility to malignant transformation, and&#x000a0;these mutations&#x000a0;are more&#x000a0;prevalent among&#x000a0;individuals of Chinese and other Southeast Asian ancestries.<xref ref-type="bibr" rid="article-25574.r32">[32]</xref>&#x000a0;The most potent risk factors for nasopharyngeal carcinoma development have been identified as major histocompatibility complex (MHC) I gene variants.<xref ref-type="bibr" rid="article-25574.r33">[33]</xref></p>
        <p>The most widely accepted theory of tumorigenesis in EBV-related&#x000a0;nasopharyngeal carcinoma (given EBV's implication in&#x000a0;various malignancies)&#x000a0;suggests&#x000a0;a clonal malignancy originating from a single, latently infected progenitor cell in the lymphocyte-rich nasopharyngeal mucosa.<xref ref-type="bibr" rid="article-25574.r34">[34]</xref>&#x000a0;A&#x000a0;hallmark of EBV-related&#x000a0;nasopharyngeal carcinoma is the necessity&#x000a0;for multiple genetic abnormalities&#x000a0;induced by latent viral genes for oncogenesis. Specifically, <italic toggle="yes">EBNA, EBER1, </italic>and<italic toggle="yes"> EBER2</italic> have been extensively studied,<xref ref-type="bibr" rid="article-25574.r35">[35]</xref><xref ref-type="bibr" rid="article-25574.r36">[36]</xref>&#x000a0;with&#x000a0;<italic toggle="yes">LMP1&#x000a0;</italic>emerging as a key oncoprotein.&#x000a0;<italic toggle="yes">LMP1</italic>&#x000a0;is&#x000a0;a potent&#x000a0;signal activator for&#x000a0;various pathways, including JNK/AP1, P13K, MAPK, and NF-&#x003ba;B.<xref ref-type="bibr" rid="article-25574.r37">[37]</xref><xref ref-type="bibr" rid="article-25574.r38">[38]</xref></p>
      </sec>
      <sec id="article-25574.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Nasopharyngeal carcinoma exhibits distinctive histopathological features. The WHO classifies&#x000a0;nasopharyngeal carcinoma into&#x000a0;3 main subtypes based on histology:</p>
        <p><bold><bold>Type 1. Keratinizing</bold>: </bold>Histologically indistinguishable from keratinizing&#x000a0;squamous cell carcinoma&#x000a0;in&#x000a0;other body sites. It exhibits apparent squamous differentiation with prominent intracellular bridges and variable keratinization, including keratin pearls. Consequently, it can be graded as well, moderate, or poorly differentiated&#x000a0;based&#x000a0;on the degree of keratinization.<xref ref-type="bibr" rid="article-25574.r39">[39]</xref></p>
        <p><bold>Type 2. Nonkeratinizing (differentiated)</bold>: Characterized by cords or trabeculae of interconnected cells with well-defined borders and little to no keratinization. The presence or absence of intracellular bridges may vary, and the tumor may exhibit&#x000a0;a resemblance to urothelial carcinoma. Typically, there is no desmoplastic response to the cancer, although the stroma may display a nonneoplastic lymphoplasmacytic infiltrate.</p>
        <p>Within the same tumor, there may exist both differentiated and nondifferentiated loci.&#x000a0;The classification of the tumor should be&#x000a0;according&#x000a0;to the dominant component. This classification of degree of differentiation is optional, as it does not carry any prognostic significance.</p>
        <p><bold>Type 3. Nonkeratinizing (undifferentiated)</bold>: Displays&#x000a0;1 of&#x000a0;2 predominant patterns on hematoxylin and eosin (H&#x00026;E) staining, though these patterns do not appear to affect prognosis:<xref ref-type="bibr" rid="article-25574.r40">[40]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Regaud pattern: Cohesive cells with indistinct margins arranged in a syncytial pattern</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Schmincke pattern: Noncohesive cells with a diffuse cellular infiltrate, resembling non-Hodgkin lymphoma</p>
          </list-item>
        </list>
        <p>The cells in this subtype typically&#x000a0;exhibit round nuclei with prominent nucleoli. There is an absence of keratinization, while increased mitoses and apoptosis are universally present. However, necrosis is infrequent.&#x000a0;Additionally, a nonneoplastic lymphoplasmacytic infiltrate is often observed in the surrounding tissue.</p>
        <p>Immunohistochemistry is crucial in characterizing nasopharyngeal carcinoma by detecting specific protein markers. Positive staining is observed for the following markers in nasopharyngeal carcinoma:<xref ref-type="bibr" rid="article-25574.r41">[41]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>EBV latent membrane Protein</p>
          </list-item>
          <list-item>
            <p>High molecular weight keratin</p>
          </list-item>
          <list-item>
            <p>Pancytokeratin</p>
          </list-item>
          <list-item>
            <p>p63</p>
          </list-item>
          <list-item>
            <p>p40</p>
          </list-item>
        </list>
        <p>Negative staining is noted for the following markers:</p>
        <list list-type="bullet">
          <list-item>
            <p>CK20</p>
          </list-item>
          <list-item>
            <p>CD45</p>
          </list-item>
          <list-item>
            <p>S100</p>
          </list-item>
          <list-item>
            <p>HMB45</p>
          </list-item>
          <list-item>
            <p>MelanA</p>
          </list-item>
          <list-item>
            <p>Desmin</p>
          </list-item>
          <list-item>
            <p>Myoglobin</p>
          </list-item>
          <list-item>
            <p>Myogenin</p>
          </list-item>
          <list-item>
            <p>CK7 (may occasionally show positivity)</p>
          </list-item>
        </list>
        <p>EBV DNA is detected in 75% to 100% of nasopharyngeal carcinoma cases using PCR or FISH.<xref ref-type="bibr" rid="article-25574.r42">[42]</xref>&#x000a0;This high detection rate underscores the significance of EBV DNA testing in confirming the presence of&#x000a0;EBV in nasopharyngeal carcinoma, aiding in accurate diagnosis and treatment planning.</p>
      </sec>
      <sec id="article-25574.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Symptoms of&#x000a0;nasopharyngeal cancer&#x000a0;are&#x000a0;stage-dependent, and most cases present at an advanced stage with a palpable neck nodal metastasis.<xref ref-type="bibr" rid="article-25574.r43">[43]</xref>&#x000a0;A solitary, painless, incidentally noted neck mass is&#x000a0;a common initial sign&#x000a0;and symptom in&#x000a0;various head and neck cancers. In adults, a new neck mass that has persisted for over 2 weeks should be presumed malignant until proven otherwise.&#x000a0;Inquiry into the onset of the neck mass, its identification method, and any antecedent upper respiratory or dental infections are crucial. Additionally, changes in the mass size and the presence of any other neck masses should be addressed.</p>
        <p>Associated symptoms such as hoarseness or voice changes, dysphagia or odynophagia, otalgia, nasal obstruction (unilateral&#x000a0;versus bilateral), epistaxis, hemoptysis, hematemesis, vision changes, headache or facial pain,&#x000a0;and persistent rhinorrhea should be carefully investigated.&#x000a0;Gathering a comprehensive social&#x000a0;history, including information on tobacco and alcohol use, prolonged sun exposure (occupational or recreational), sunscreen use, and occupational history, is essential. Family and ethnic background, particularly in individuals of Asian ancestry, should be obtained. A thorough past medical history, including any previous head and neck cancers, skin cancers, or immunosuppression, should also be documented.</p>
        <p>A comprehensive physical examination of the head and neck is imperative.&#x000a0;The skin and scalp should be examined for visible or palpable lesions, and&#x000a0;investigation into encountered scars is essential to determine whether they represent previously excised malignant or premalignant lesions.</p>
        <p>The otologic examination is necessary to assess the middle ears for effusion, with particular attention to unilateral effusion, as it may indicate nasopharyngeal obstruction in adults. Anterior rhinoscopy&#x000a0;is crucial for detecting&#x000a0;visible lesions before and after administering topical decongestant. Nasal endoscopy&#x000a0;is essential for a&#x000a0;thorough evaluation of the nasopharynx. While some adenoid tissue may persist into adulthood, the presence of prominent or asymmetric adenoids&#x000a0;in adults is a cause for concern.</p>
        <p>An oral cavity and oropharyngeal examination should focus&#x000a0;on mucosal lesions, dental health, and palpation of the tongue, base of the tongue, and floor of the mouth. Flexible laryngoscopy&#x000a0;is necessary to examine the tongue base, oropharynx, and hypopharynx thoroughly. Any masses or lymphadenopathy, thyroid nodules, and stridor or hoarseness should be carefully noted during the neck examination. A cranial nerve examination is mandatory,&#x000a0;particularly in identifying deficits or asymmetries.</p>
      </sec>
      <sec id="article-25574.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>A thorough history and physical examination of the head and neck are paramount, guiding all subsequent workups. If a suspicious mass is identified in the oral cavity, oropharynx, thyroid, or hypopharynx, a&#x000a0;computed tomography (CT) scan with intravenous (IV) contrast of the neck should be obtained. &#x000a0;</p>
        <p>The choice of subsequent imaging for a suspicious mass in the nasopharynx has been historically controversial. CT with IV contrast&#x000a0;has long&#x000a0;been the preferred&#x000a0;imaging modality for initial staging. CT excels in determining bony invasion and evaluating the relevant nodal basins and is often required for treatment planning in radiation therapy.<xref ref-type="bibr" rid="article-25574.r44">[44]</xref>&#x000a0;However, CT is less accurate in&#x000a0;assessing the extent of soft-tissue involvement, and&#x000a0;its resolution may be inadequate&#x000a0;for detecting extremely small tumors, where&#x000a0;magnetic resonance imaging&#x000a0;(MRI) or positron emission tomography and CT (PET-CT) can be more helpful, respectively.<xref ref-type="bibr" rid="article-25574.r45">[45]</xref>&#x000a0;</p>
        <p>Practical and logistical considerations may lead to obtaining a CT scan as the first-line imaging modality today, especially where&#x000a0;CT is more widely available or required for insurance reasons. CT is also&#x000a0;chosen when patients are unable to&#x000a0;undergo an MRI due to implanted metal or claustrophobia.&#x000a0;In cases where CT is used, obtaining fine-cut (1 to 2mm) images through the nasopharynx&#x000a0;is crucial for optimal&#x000a0;evaluation of the presumed tumor and the neural foramina of the skull base.<xref ref-type="bibr" rid="article-25574.r46">[46]</xref>&#x000a0;</p>
        <p>MRI of the face and neck is the best&#x000a0;modality&#x000a0;for evaluating the extent of the primary tumor (T stage) with&#x000a0;the utmost precision. It surpasses other imaging techniques in detecting subclinical primary tumors that&#x000a0;might be missed on endoscopy and CT scans.<xref ref-type="bibr" rid="article-25574.r47">[47]</xref>&#x000a0;While CT scans also effectively assess cervical lymph nodes, MRI is&#x000a0;considered an acceptable&#x000a0;alternative.<xref ref-type="bibr" rid="article-25574.r48">[48]</xref>&#x000a0;However, a PET scan is strongly recommended&#x000a0;for evaluating metastatic disease (M stage)&#x000a0;due to the&#x000a0;tendency of nasopharyngeal cancers&#x000a0;to metastasize, as well as&#x000a0;its capability to&#x000a0;identify subclinical nodal metastases.</p>
        <p>A histologic diagnosis is&#x000a0;essential for accurate&#x000a0;staging and treatment planning. This can be effectively achieved through&#x000a0;an endoscopic biopsy of a nasopharyngeal mass performed under local or general anesthesia. In cases where the primary tumor is not readily evident clinically, fine needle aspiration of the&#x000a0;metastatic neck node can be conducted for cytology and EBV testing. An EBV-positive nodal metastasis can be safely assumed to originate from a nasopharyngeal primary, facilitating staging, prognosis, and treatment decisions, even without a visible primary lesion.<xref ref-type="bibr" rid="article-25574.r49">[49]</xref><xref ref-type="bibr" rid="article-25574.r50">[50]</xref><xref ref-type="bibr" rid="article-25574.r51">[51]</xref>&#x000a0;</p>
        <p>The standard of care for these patients involves an interprofessional evaluation, typically conducted in a tumor board or&#x000a0;another&#x000a0;multidisciplinary clinic. This collaborative approach includes consultation with medical oncology, radiation oncology, surgical oncology, radiology, and pathology.</p>
      </sec>
      <sec id="article-25574.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Nonsurgical approaches are the primary mode of treatment for most nasopharyngeal cancers. The anatomical challenges posed by the nasopharynx&#x000a0;make surgical access difficult, and the typical late-stage presentation of&#x000a0;nasopharyngeal carcinoma often renders primary tumors unresectable due to the involvement of bony structures that cannot be safely removed.&#x000a0;Although exceptionally&#x000a0;rare, small primary&#x000a0;nasopharyngeal carcinoma cases may be considered for surgical treatment using endoscopic or transpalatal approaches, primarily documented in case-series reports.<xref ref-type="bibr" rid="article-25574.r52">[52]</xref>&#x000a0;</p>
        <p>In instances of local failure after primary chemo and radiation therapy, nasopharyngectomy (either endoscopic&#x000a0;or open) has been employed. Notably, the most extensive series reported more than 80% local control at&#x000a0;2 years postoperatively.<xref ref-type="bibr" rid="article-25574.r53">[53]</xref>&#x000a0;However, it is essential to recognize that surgical intervention in nasopharyngeal cancer remains a specialized and infrequently utilized option.</p>
        <p>Nonsurgical treatment for nasopharyngeal carcinoma includes radiation therapy, chemotherapy, or a combination of modalities, depending on the stage of the tumor. Efforts should be made to enroll all patients in available clinical trials to explore innovative and potentially more effective treatment approaches.<xref ref-type="bibr" rid="article-25574.r9">[9]</xref></p>
        <p>
<bold>Radiation Therapy</bold>
</p>
        <p>Radiation therapy is the essential treatment modality for nasopharyngeal carcinoma. The introduction of intensity-modulated radiation therapy in the 1990s has&#x000a0;established&#x000a0;a new standard of care. Consensus guidelines for tumor delineation&#x000a0;in&#x000a0;nasopharyngeal carcinoma have been established to optimize&#x000a0;oncologic control&#x000a0;while minimizing toxicity to&#x000a0;critical surrounding structures such as the eyes, brain, middle ear, and temporomandibular joint.<xref ref-type="bibr" rid="article-25574.r54">[54]</xref>&#x000a0;In stage I nasopharyngeal carcinoma, radiation therapy is used as a single-modality treatment,&#x000a0;and chemotherapy&#x000a0;is added for more advanced-stage disease, as discussed later.</p>
        <p>Traditionally, treatment fields for&#x000a0;nasopharyngeal carcinoma encompassed the entire (bilateral) nasopharynx, along with the at-risk nodal basins of the retropharynx and bilateral neck. The fossa of Rosenmuller is the most common site of origin within the nasopharynx, representing over 80% of nasopharyngeal carcinoma cases, with the tumor remaining unilateral in up to 90% of cases even as the tumor expands.<xref ref-type="bibr" rid="article-25574.r55">[55]</xref><xref ref-type="bibr" rid="article-25574.r56">[56]</xref>&#x000a0;Recognizing the potential to reduce radiation dose volumes, the deliberate exclusion of the contralateral nasopharynx and surrounding critical structures in&#x000a0;the NRG HN001 trial resulted in up to 62% reduction in CTV2 volume and a decreased dose to multiple critical structures by up to 33%.<xref ref-type="bibr" rid="article-25574.r57">[57]</xref></p>
        <p>Nasopharyngeal carcinoma&#x000a0;presents a high risk of nodal metastasis, often being the primary complaint at the time of diagnosis. Except for stage I disease, the at-risk nodal basins must be treated.&#x000a0;While the level II (jugulodigastric) nodes were traditionally considered&#x000a0;the most frequent site of metastasis in nasopharyngeal carcinoma, modern imaging techniques have identified retropharyngeal nodes&#x000a0;as the&#x000a0;most common metastatic site.<xref ref-type="bibr" rid="article-25574.r58">[58]</xref>&#x000a0;Nodal metastatic progression&#x000a0;typically follows a stepwise pattern: first, the retropharyngeal notes, then proceeding caudally along the deep cervical nodes to levels III, IV, and V. Level I, the intraparotid nodes, supraclavicular nodes, and level VI were found to be highly low-risk basins in a meta-analysis of over 10,000 nodes.<xref ref-type="bibr" rid="article-25574.r59">[59]</xref>&#x000a0;</p>
        <p>An important caveat relates to level Ib. Sparing the submandibular glands to minimize xerostomia is often desirable, mainly if level I is low-risk. If the level II nodes are greater than 2 cm or display extracapsular spread, the level Ib nodes are considered higher risk and should be included in the treatment fields.<xref ref-type="bibr" rid="article-25574.r60">[60]</xref>&#x000a0;Current international guidelines recommend a total dose of 70 Gy to high-risk clinical target volume and 50 to 60 Gy to low- and intermediate-risk clinical target volume.<xref ref-type="bibr" rid="article-25574.r51">[51]</xref>&#x000a0;</p>
        <p>In cases of treatment failures, most local failures occurred within the high-dose fields, prompting interest in de-escalation to&#x000a0;reduce&#x000a0;radiation therapy-associated morbidity to surrounding structures.<xref ref-type="bibr" rid="article-25574.r61">[61]</xref>&#x000a0;This is an area of active research, with trials demonstrating encouraging short-term results after gradient dosing in dose prescription, as opposed to the more traditional 2-tiered dosing.<xref ref-type="bibr" rid="article-25574.r62">[62]</xref>&#x000a0;Induction chemotherapy has also been employed as a method to&#x000a0;identify tumors responsive to de-escalation,&#x000a0;especially in the pediatric population, where the long-term consequences of facial radiation are significant. Promising results have been reported in clinical trials, such as the NPC-2003-GPOH/DCOG trial, using various induction chemotherapy protocols for de-escalation, with 5-year, event-free survival rates of 77% to 91% reported after de-escalation to 45-68 Gy.<xref ref-type="bibr" rid="article-25574.r63">[63]</xref></p>
        <p>
<bold>Chemotherapy</bold>
</p>
        <p>A phase III intergroup study&#x000a0;demonstrated a statistically significant improvement in progression-free survival and overall survival for patients with&#x000a0;stage III and locally advanced stage IV nasopharyngeal carcinoma when treated with bimodality&#x000a0;therapy comprising radiation therapy with systemic chemotherapy.<xref ref-type="bibr" rid="article-25574.r64">[64]</xref><xref ref-type="bibr" rid="article-25574.r65">[65]</xref><xref ref-type="bibr" rid="article-25574.r66">[66]</xref>&#x000a0;These early studies have formed the&#x000a0;foundation&#x000a0;of current international treatment guidelines for advanced-stage nasopharyngeal carcinoma. The most current international recommendations, jointly issued by the American Society of Clinical Oncology and the Chinese Society of Clinical Oncology, advocate the following approaches:</p>
        <list list-type="bullet">
          <list-item>
            <p>For patients with stage II disease, the role of chemotherapy depends on the status of the lymph nodes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In T2N0 disease, chemotherapy is not routinely offered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In T1-2N1 disease, concurrent chemoradiation therapy is recommended.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with T3N0 disease, concurrent chemoradiation therapy&#x000a0;is recommended, and&#x000a0;induction chemotherapy or adjuvant chemotherapy may be offered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with all other stage III-IVA disease, concurrent chemoradiation therapy should be administered,&#x000a0;along with&#x000a0;either induction or adjuvant chemotherapy.<xref ref-type="bibr" rid="article-25574.r67">[67]</xref></p>
          </list-item>
        </list>
        <p>Concurrent chemotherapeutic for nasopharyngeal carcinoma typically involves the use of cisplatin, which remains the agent of choice. The administration of cisplatin varies as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients without contraindications, cisplatin is ideally administered concurrently with radiation therapy as follows:<xref ref-type="bibr" rid="article-25574.r68">[68]</xref><xref ref-type="bibr" rid="article-25574.r69">[69]</xref><xref ref-type="bibr" rid="article-25574.r70">[70]</xref><xref ref-type="bibr" rid="article-25574.r71">[71]</xref><xref ref-type="bibr" rid="article-25574.r72">[72]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>Weekly 40 mg/m<sup>2&#x000a0;</sup>for 7 doses or,</p></list-item><list-item><p>Tri-weekly 100 mg/m<sup>2&#x000a0;</sup>for 3 doses</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with contraindications to cisplatin may use the following treatment options:<xref ref-type="bibr" rid="article-25574.r67">[67]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>Carboplatin AUC5-6 triweekly</p></list-item><list-item><p>Nedaplatin 100 mg/m<sup>2</sup> triweekly</p></list-item><list-item><p>Oxaliplatin 70 mg/m<sup>2</sup>&#x000a0;</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If&#x000a0;a patient&#x000a0;cannot&#x000a0;tolerate any platinum-based chemotherapy, concurrent use of capecitabine, tegafur, and 5-fluorouracil (5-FU) radiation therapy is also an option.<xref ref-type="bibr" rid="article-25574.r73">[73]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Induction chemotherapeutic agents:</bold>
</p>
        <p>Platinum-based agents&#x000a0;are recommended for all&#x000a0;patients&#x000a0;undergoing&#x000a0;induction chemotherapy, with&#x000a0;a notable increase in overall survival&#x000a0;documented in a landmark phase II study in 2009. This study showed an improvement in overall survival from 68% to 94% with the addition of&#x000a0;2 cycles of docetaxel.<xref ref-type="bibr" rid="article-25574.r74">[74]</xref>&#x000a0;Current recommended induction regimens include:<xref ref-type="bibr" rid="article-25574.r75">[75]</xref><xref ref-type="bibr" rid="article-25574.r76">[76]</xref><xref ref-type="bibr" rid="article-25574.r77">[77]</xref><xref ref-type="bibr" rid="article-25574.r78">[78]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Docetaxel 60 to 75 mg/m<sup>2</sup>&#x000a0;on day 1; cisplatin 60 to 75 mg/m<sup>2</sup>&#x000a0;on day 1; 5-FU 600 to 750 mg/m<sup>2</sup> per day, continuous infusion on days 1 to 5</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gemcitabine 1000 mg/m<sup>2</sup>&#x000a0;on day 1 and day 8; cisplatin 80 mg/m<sup>2</sup>&#x000a0;on day 1</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cisplatin 80 to 100mg/m<sup>2</sup>&#x000a0; on day 1; 5-FU 800 to 1000 mg/m<sup>2</sup> per day, continuous infusion on days 1 to 5</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cisplatin 100 mg/m<sup>2</sup>&#x000a0;on day 1; capecitabine 2000 mg/m<sup>2</sup> per day on days 1 to 14</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Docetaxel 75 mg/m<sup>2</sup>&#x000a0;on day 1; cisplatin 75mg/m<sup>2</sup>&#x000a0;on day 1.</p>
          </list-item>
        </list>
        <p>
<bold>Adjuvant chemotherapeutic agents:</bold>
</p>
        <p>Platinum-based agents&#x000a0;are essential&#x000a0;in all patients receiving adjuvant chemotherapy for&#x000a0;nasopharyngeal carcinoma unless contraindicated.<xref ref-type="bibr" rid="article-25574.r68">[68]</xref>&#x000a0;The preferred regimen is:</p>
        <list list-type="bullet">
          <list-item>
            <p>Cisplatin 80 mg/m<sup>2</sup>&#x000a0;on day 1 or 20 mg/m<sup>2</sup>&#x000a0;on days 1 to 5; 5-FU 1000 mg/m<sup>2</sup> per day, continuous infusion on days 1 to 4 or 800 mg/m<sup>2</sup> per day, continuous infusion on days 1 to 5. This is to be administered every&#x000a0;4 weeks for 3 cycles.<xref ref-type="bibr" rid="article-25574.r79">[79]</xref><xref ref-type="bibr" rid="article-25574.r71">[71]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Carboplatin may be used if cisplatin is intolerable and can be combined with 5-FU.<xref ref-type="bibr" rid="article-25574.r80">[80]</xref>&#x000a0;Enrolling in a clinical trial is recommended, if possible, in the presence of a significant contraindication to platinum-based agents. Nonplatinum-based agents in&#x000a0;nasopharyngeal&#x000a0;treatment remain experimental and should not be routinely offered.<xref ref-type="bibr" rid="article-25574.r67">[67]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25574.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Several conditions may present with symptoms similar to nasopharyngeal carcinoma, making differential diagnosis crucial. Some of the conditions to consider include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Enlarged adenoids/HIV-associated lymphatic hyperplasia</p>
          </list-item>
          <list-item>
            <p>Antrochoanal polyp</p>
          </list-item>
          <list-item>
            <p>Inverting&#x000a0; papilloma</p>
          </list-item>
          <list-item>
            <p>Vascular malformation</p>
          </list-item>
          <list-item>
            <p>Malignancy</p>
          </list-item>
          <list-item>
            <p>Nasal polyposis</p>
          </list-item>
          <list-item>
            <p>Infectious mononucleosis</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Sarcoma</p>
          </list-item>
          <list-item>
            <p>Adenocarcinoma</p>
          </list-item>
          <list-item>
            <p>Wegener granulomatosis</p>
          </list-item>
          <list-item>
            <p>Rhinosporidiosis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25574.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis of nasopharyngeal carcinoma is closely linked to&#x000a0;its stage at presentation. A more favorable survival outcome&#x000a0;is observed in stage I disease,&#x000a0;whereas&#x000a0;stage IV disease is associated with the poorest prognosis. The overall relative 5-year survival rate for stage I&#x000a0;nasopharyngeal carcinoma&#x000a0;is 82%.&#x000a0;However, for&#x000a0;stage II disease, this&#x000a0;rate decreases&#x000a0;to 72%, and in the case of stage IV disease, the 5-year relative survival rate drops&#x000a0;further to 49%<xref ref-type="bibr" rid="article-25574.r81">[81]</xref><xref ref-type="bibr" rid="article-25574.r82">[82]</xref>.</p>
        <p>After initial treatment,&#x000a0;patients should maintain regular follow-ups with their oncologist for cancer surveillance. This involves&#x000a0;physical examinations, nasal endoscopy, and&#x000a0;possibly&#x000a0;serum labwork for EBV DNA and thyroid function due to the risk of post-radiotherapy hypothyroidism. Detectable EBV DNA levels post-treatment are associated with an unfavorable prognosis, making it an established negative prognostic marker for nasopharyngeal carcinoma.<xref ref-type="bibr" rid="article-25574.r83">[83]</xref>&#x000a0;However, the&#x000a0;use&#x000a0;of circulating EBV DNA in monitoring after chemoradiotherapy for&#x000a0;nasopharyngeal carcinoma remains under investigation.<xref ref-type="bibr" rid="article-25574.r84">[84]</xref>&#x000a0;</p>
        <p>Currently, the standard of care for posttreatment surveillance&#x000a0;includes physical examination and nasal endoscopy,&#x000a0;with&#x000a0;the&#x000a0;optimal&#x000a0;timeline and frequency being&#x000a0;a subject of debate.&#x000a0;Many experts&#x000a0;recommend frequent screening&#x000a0;in the first 12 to 24 months post-treatment, such as every 3 months. This&#x000a0;may be extended&#x000a0;to every 4 to 6 months&#x000a0;during years 3 to 5 post-treatment and annually after that.<xref ref-type="bibr" rid="article-25574.r85">[85]</xref>&#x000a0;</p>
        <p>Most centers conduct a posttreatment PET-CT scan 3 months after completing radiotherapy, followed by a 1-year posttreatment PET-CT if the initial scan is normal.<xref ref-type="bibr" rid="article-25574.r86">[86]</xref>&#x000a0; If&#x000a0;both scans&#x000a0;are negative, further surveillance imaging may not be recommended in nonendemic areas.<xref ref-type="bibr" rid="article-25574.r87">[87]</xref><xref ref-type="bibr" rid="article-25574.r88">[88]</xref>&#x000a0;However, these guidelines may vary, and individualized approaches may be considered based on patient-specific factors and evolving research.</p>
      </sec>
      <sec id="article-25574.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Nasopharyngeal carcinoma and its treatment can lead to various complications. Here are some potential complications associated with nasopharyngeal carcinoma:</p>
        <p>
<bold>Treatment-Related Complications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Radiation therapy adverse effects: Radiation therapy can cause&#x000a0;adverse effects such as mucositis, xerostomia (dry mouth), radiation dermatitis, and fatigue.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chemotherapy adverse effects: Chemotherapy may lead to nausea, vomiting, fatigue, hair loss, and increased susceptibility to infections.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Immunosuppression: Cancer and its treatments can weaken the immune system, making individuals more susceptible to infections.</p>
          </list-item>
        </list>
        <p>
<bold>Long-Term Adverse&#x000a0;Effects</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Xerostomia: A dry mouth due to reduced salivary gland function, often caused by radiation therapy, can lead to difficulties in swallowing and speaking and an increased risk of dental issues.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hearing loss: Depending on the location and extent of the tumor, hearing loss may occur, primarily if the cancer affects the nearby structures.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cognitive issues: Radiation therapy to the head and neck region may affect cognitive function.</p>
          </list-item>
        </list>
        <p>
<bold>Metastasis and Recurrence</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Distant metastasis:&#x000a0;Nasopharyngeal carcinoma&#x000a0;has a propensity to metastasize to distant organs.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Local recurrence: Despite treatment, local tumor recurrence may occur, necessitating further interventions.</p>
          </list-item>
        </list>
        <p>
<bold>Secondary Cancers</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment-related secondary cancers: Long-term survivors of&#x000a0;nasopharyngeal carcinoma may be at a higher risk of developing secondary cancers, often related to the treatment received.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25574.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Deterrence and patient education for nasopharyngeal carcinoma encompasses a range of strategies aimed at preventing the development of the disease and informing individuals about various aspects related to&#x000a0;nasopharyngeal carcinoma. Education efforts emphasize key risk factors, such as EBV infection, family history, and geographic predispositions, encouraging individuals to avoid known risk factors like tobacco use and excessive alcohol consumption.</p>
        <p>Lifestyle modifications, including a healthy diet and regular physical activity, are promoted for risk reduction. Emphasis is placed on the significance of early detection through regular health check-ups and screenings, with information about&#x000a0;nasopharyngeal carcinoma symptoms provided to the public. Considering the increased risk in specific regions and among certain ethnic groups, education addresses geographic and ethnic considerations, urging vigilance and prompt medical attention in high-risk populations.</p>
        <p>Awareness about EBV infection and hygiene practices to reduce transmission is highlighted, alongside genetic counseling services for those with a family history of nasopharyngeal carcinoma.&#x000a0;Encouraging regular health check-ups and providing information on available treatment options, potential&#x000a0;adverse effects, and prognosis are integral aspects.</p>
      </sec>
      <sec id="article-25574.s14" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Key facts to keep in mind about nasopharyngeal carcinoma are as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nasopharyngeal carcinoma&#x000a0;has a distinct geographic distribution, with a higher incidence in Southeast Asia, particularly in regions like China.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>EBV infection is strongly associated with nasopharyngeal carcinoma, especially in endemic areas.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Genetic factors, family history, and environmental exposures, such as consumption of preserved foods containing nitrosamines, are implicated.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Smoking and alcohol use may be risk factors in nonendemic areas.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Nasopharyngeal carcinoma&#x000a0;is classified into&#x000a0;3 histological subtypes by the WHO: keratinizing squamous cell carcinoma (Type 1), differentiated nonkeratinizing carcinoma (Type 2), and undifferentiated carcinoma (Type 3).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Symptoms may include a painless neck mass, otitis media, nasal obstruction, and other head and neck-related symptoms.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnosis often occurs at an advanced stage due to the anatomical location of the nasopharynx.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diagnosis is confirmed through biopsy, often via endoscopic procedures.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Imaging studies such as CT and MRI are used for staging and treatment planning.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>EBV DNA testing may be utilized for screening and monitoring.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Chemotherapy is often used in combination with radiation for more advanced stages.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Surgery is rarely employed due to the challenging anatomical location of the nasopharynx.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Prognosis is stage-dependent, with Stage I having a more favorable outlook compared to Stage IV.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25574.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Collaboration among healthcare professionals is paramount in providing comprehensive, patient-centered care for nasopharyngeal carcinoma. Physicians and advanced practitioners should demonstrate proficiency in diagnosis, staging, and treatment planning, incorporating surgical skills and expertise in chemotherapy or immunotherapy. Nurses are vital in supportive care, symptom management, and patient education, while pharmacists ensure safe medication administration.</p>
        <p>Regular interdisciplinary tumor board meetings facilitate collective decision-making, while an ethical approach involves informed consent and cultural competence. Effective interprofessional communication is maintained through regular team meetings and clear patient handovers, and care coordination involves patient navigation services and post-treatment follow-up plans. This collaborative approach optimizes patient outcomes, enhances safety, and improves the quality of care for individuals with nasopharyngeal carcinoma.</p>
      </sec>
      <sec id="article-25574.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25574&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25574">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/nasopharyngeal-cancer/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25574">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25574/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25574">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25574.s17">
        <title>References</title>
        <ref id="article-25574.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Qi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Characteristics of local extension based on tumor distribution in nasopharyngeal carcinoma and proposed clinical target volume delineation.</article-title>
            <source>Radiother Oncol</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>183</volume>
            <fpage>109595</fpage>
            <pub-id pub-id-type="pmid">36870606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bei</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Su</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Lou</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>QS</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Khoo</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Pua</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Hildesheim</surname>
                <given-names>A</given-names>
              </name>
              <collab>International Nasopharyngeal Carcinoma (NPC) Genetics Working Group</collab>
            </person-group>
            <article-title>A GWAS Meta-analysis and Replication Study Identifies a Novel Locus within CLPTM1L/TERT Associated with Nasopharyngeal Carcinoma in Individuals of Chinese Ancestry.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>188</fpage>
            <page-range>188-192</page-range>
            <pub-id pub-id-type="pmid">26545403</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Challapalli</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Adjei Boakye</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Antisdel</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Osazuwa-Peters</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Survival differences in nasopharyngeal carcinoma among racial and ethnic minority groups in the United States: A retrospective cohort study.</article-title>
            <source>Clin Otolaryngol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-20</page-range>
            <pub-id pub-id-type="pmid">30216675</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liao</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>YL</given-names>
              </name>
            </person-group>
            <article-title>Feature Reviews of the Molecular Mechanisms of Nasopharyngeal Carcinoma.</article-title>
            <source>Biomedicines</source>
            <year>2023</year>
            <month>May</month>
            <day>25</day>
            <volume>11</volume>
            <issue>6</issue>
            <pub-id pub-id-type="pmid">37371623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Jun</month>
            <day>14</day>
            <volume>24</volume>
            <issue>12</issue>
            <pub-id pub-id-type="pmid">37373272</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xiong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Outcomes of Nasopharyngeal Carcinoma by Epstein-Barr Virus Status in the Chinese Population: A Multicenter Investigation.</article-title>
            <source>J Clin Med</source>
            <year>2023</year>
            <month>Apr</month>
            <day>20</day>
            <volume>12</volume>
            <issue>8</issue>
            <pub-id pub-id-type="pmid">37109338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benesch</surname>
                <given-names>MGK</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>SBL</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of Undifferentiated Carcinomas.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Nov</month>
            <day>25</day>
            <volume>14</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">36497299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Geng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qin</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Dural and Multiple Brain Metastases From Basaloid Nasopharyngeal Carcinoma: Case Report and Literature Review.</article-title>
            <source>Front Oncol</source>
            <year>2021</year>
            <volume>11</volume>
            <fpage>665652</fpage>
            <pub-id pub-id-type="pmid">34336659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>De Ravin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Suresh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brody</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Rajasekaran</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A comprehensive review and characterization of nasopharyngeal carcinoma clinical trials.</article-title>
            <source>World J Otorhinolaryngol Head Neck Surg</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>174</fpage>
            <page-range>174-182</page-range>
            <pub-id pub-id-type="pmid">37383331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fu</surname>
                <given-names>ZT</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>KX</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>WQ</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Incidence and mortality of nasopharyngeal carcinoma in China, 2014].</article-title>
            <source>Zhonghua Zhong Liu Za Zhi</source>
            <year>2018</year>
            <month>Aug</month>
            <day>23</day>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>566</fpage>
            <page-range>566-571</page-range>
            <pub-id pub-id-type="pmid">30139025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adoga</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Kokong</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Ma'an</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Silas</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Dauda</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Yaro</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mugu</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Mgbachi</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Yabak</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology, treatment, and determinants of outcome of primary head and neck cancers at the Jos University Teaching Hospital.</article-title>
            <source>South Asian J Cancer</source>
            <year>2018</year>
            <season>Jul-Sep</season>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>183</fpage>
            <page-range>183-187</page-range>
            <pub-id pub-id-type="pmid">30112335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanchard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Moya-Plana</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignon</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Even</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bidault</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Temam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ruffier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[New developments in the management of nasopharyngeal carcinoma].</article-title>
            <source>Cancer Radiother</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>6-7</issue>
            <fpage>492</fpage>
            <page-range>492-495</page-range>
            <pub-id pub-id-type="pmid">30087054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Romdhoni</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rejeki</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Milla</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Melbiarta</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Visuddho</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Nugraha</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Risk Factors Associated with Nasopharyngeal Cancer Incidences in Indonesia: A Systematic Review and Meta-Analysis.</article-title>
            <source>Asian Pac J Cancer Prev</source>
            <year>2023</year>
            <month>Apr</month>
            <day>01</day>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>1105</fpage>
            <page-range>1105-1111</page-range>
            <pub-id pub-id-type="pmid">37116129</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kondo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okuno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Murata</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dochi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wakisaka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mizokami</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Moriyama-Kita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komori</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hirai</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ueno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Endo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sugimoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yoshizaki</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>EBV genome variations enhance clinicopathological features of nasopharyngeal carcinoma in a non-endemic region.</article-title>
            <source>Cancer Sci</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>113</volume>
            <issue>7</issue>
            <fpage>2446</fpage>
            <page-range>2446-2456</page-range>
            <pub-id pub-id-type="pmid">35485636</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wee</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Loong</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>CN</given-names>
              </name>
            </person-group>
            <article-title>Is nasopharyngeal cancer really a "Cantonese cancer"?</article-title>
            <source>Chin J Cancer</source>
            <year>2010</year>
            <month>May</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>517</fpage>
            <page-range>517-26</page-range>
            <pub-id pub-id-type="pmid">20426903</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>ZL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>BY</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>ZU</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>LQ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Achilli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Semino</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Torroni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>QP</given-names>
              </name>
            </person-group>
            <article-title>Mitogenome evidence shows two radiation events and dispersals of matrilineal ancestry from northern coastal China to the Americas and Japan.</article-title>
            <source>Cell Rep</source>
            <year>2023</year>
            <month>May</month>
            <day>30</day>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>112413</fpage>
            <pub-id pub-id-type="pmid">37164007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lian</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Salted fish and processed foods intake and nasopharyngeal carcinoma risk: a dose-response meta-analysis of observational studies.</article-title>
            <source>Eur Arch Otorhinolaryngol</source>
            <year>2022</year>
            <month>May</month>
            <volume>279</volume>
            <issue>5</issue>
            <fpage>2501</fpage>
            <page-range>2501-2509</page-range>
            <pub-id pub-id-type="pmid">35094122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kara</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ertan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>D&#x000fc;zova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>&#x000c7;a&#x0011f;layan</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>K&#x000f6;ksal</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Familial clustering of nasopharyngeal carcinoma in the family of an adolescent with nasopharyngeal carcinoma.</article-title>
            <source>Turk J Pediatr</source>
            <year>2022</year>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>1130</fpage>
            <page-range>1130-1135</page-range>
            <pub-id pub-id-type="pmid">36583896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>WQ</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>XH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>XZ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>YZ</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Genomic landscape of Epstein-Barr virus in familial nasopharyngeal carcinoma.</article-title>
            <source>J Gen Virol</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>103</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">35349400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>HX</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>DY</given-names>
              </name>
            </person-group>
            <article-title>[The clinical significance of EBV DNA analysis in nasopharyngeal carcinoma screening].</article-title>
            <source>Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>4</issue>
            <fpage>298</fpage>
            <page-range>298-301</page-range>
            <pub-id pub-id-type="pmid">29798510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kong</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>XG</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of circulating Epstein-Barr virus DNA level post-induction chemotherapy for patients with nasopharyngeal carcinoma: A recursive partitioning risk stratification analysis.</article-title>
            <source>Radiother Oncol</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>185</volume>
            <fpage>109721</fpage>
            <pub-id pub-id-type="pmid">37244356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gihbid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benzeid</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Faouzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>El Alami</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tawfiq</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Benchakroun</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bendahhou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Benider</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Guensi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khaali</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chaoui</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>El Mzibri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cadi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Khyatti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The Dynamic Change in Plasma Epstein-Barr Virus DNA Load over a Long-Term Follow-Up Period Predicts Prognosis in Nasopharyngeal Carcinoma.</article-title>
            <source>Viruses</source>
            <year>2022</year>
            <month>Dec</month>
            <day>25</day>
            <volume>15</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">36680107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>XM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>ZW</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>YK</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>FY</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factor analysis in patients with early-stage nasopharyngeal carcinoma in the USA.</article-title>
            <source>Future Oncol</source>
            <year>2023</year>
            <month>May</month>
            <volume>19</volume>
            <issue>15</issue>
            <fpage>1063</fpage>
            <page-range>1063-1072</page-range>
            <pub-id pub-id-type="pmid">37283023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Adami</surname>
                <given-names>HO</given-names>
              </name>
            </person-group>
            <article-title>The enigmatic epidemiology of nasopharyngeal carcinoma.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>15</volume>
            <issue>10</issue>
            <fpage>1765</fpage>
            <page-range>1765-77</page-range>
            <pub-id pub-id-type="pmid">17035381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friborg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wohlfahrt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Melbye</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Familial risk and clustering of nasopharyngeal carcinoma in Guangdong, China.</article-title>
            <source>Cancer</source>
            <year>2005</year>
            <month>Jan</month>
            <day>01</day>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>211; author reply 211</fpage>
            <page-range>211; author reply 211-2</page-range>
            <pub-id pub-id-type="pmid">15540234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liao</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Otim</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Legason</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>Ogwang</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kerchan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tenge</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Were</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kuremu</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Wekesa</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Masalu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kawira</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ayers</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Pfeiffer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goedert</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mbulaiteye</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr Virus in Burkitt Lymphoma in Africa Reveals a Limited Set of Whole Genome and <italic>LMP-1</italic> Sequence Patterns: Analysis of Archival Datasets and Field Samples From Uganda, Tanzania, and Kenya.</article-title>
            <source>Front Oncol</source>
            <year>2022</year>
            <volume>12</volume>
            <fpage>812224</fpage>
            <pub-id pub-id-type="pmid">35340265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reffai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mesmoudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Derkaoui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ghailani Nourouti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barakat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sellal</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mallick</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bennani Mechita</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological Profile and Clinicopathological, Therapeutic, and Prognostic Characteristics of Nasopharyngeal Carcinoma in Northern Morocco.</article-title>
            <source>Cancer Control</source>
            <year>2021</year>
            <season>Jan-Dec</season>
            <volume>28</volume>
            <fpage>10732748211050587</fpage>
            <pub-id pub-id-type="pmid">34664512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haugen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moger</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Tretli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Aalen</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Grotmol</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Age-incidence curves of nasopharyngeal carcinoma worldwide: bimodality in low-risk populations and aetiologic implications.</article-title>
            <source>Cancer Epidemiol Biomarkers Prev</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>17</volume>
            <issue>9</issue>
            <fpage>2356</fpage>
            <page-range>2356-65</page-range>
            <pub-id pub-id-type="pmid">18768504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bray</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ferlay</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soerjomataram</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Torre</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Jemal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.</article-title>
            <source>CA Cancer J Clin</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>68</volume>
            <issue>6</issue>
            <fpage>394</fpage>
            <page-range>394-424</page-range>
            <pub-id pub-id-type="pmid">30207593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>WZ</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>YQ</given-names>
              </name>
            </person-group>
            <article-title>Age-dependent changes of gender disparities in nasopharyngeal carcinoma survival.</article-title>
            <source>Biol Sex Differ</source>
            <year>2021</year>
            <month>Jan</month>
            <day>30</day>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">33516267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>[Effect of A20 gene induced silencing on the biological behaviors of human nasopharyngeal carcinoma cell].</article-title>
            <source>Zhonghua Yi Xue Za Zhi</source>
            <year>2018</year>
            <month>Jun</month>
            <day>26</day>
            <volume>98</volume>
            <issue>24</issue>
            <fpage>1956</fpage>
            <page-range>1956-1961</page-range>
            <pub-id pub-id-type="pmid">29996290</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>QS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>LZ</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Jia</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Pedergnana</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bei</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Adami</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhai</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma.</article-title>
            <source>Nat Genet</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>1131</fpage>
            <page-range>1131-1136</page-range>
            <pub-id pub-id-type="pmid">31209392</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Su</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Hildesheim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Human leukocyte antigens and epstein-barr virus-associated nasopharyngeal carcinoma: old associations offer new clues into the role of immunity in infection-associated cancers.</article-title>
            <source>Front Oncol</source>
            <year>2013</year>
            <month>Dec</month>
            <day>09</day>
            <volume>3</volume>
            <fpage>299</fpage>
            <pub-id pub-id-type="pmid">24367763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hau</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Lung</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Mak</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>600</fpage>
            <pub-id pub-id-type="pmid">32528868</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsao</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Epstein-Barr virus infection and nasopharyngeal carcinoma.</article-title>
            <source>Philos Trans R Soc Lond B Biol Sci</source>
            <year>2017</year>
            <month>Oct</month>
            <day>19</day>
            <volume>372</volume>
            <issue>1732</issue>
            <pub-id pub-id-type="pmid">28893937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsao</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Tsang</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>To</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Lo</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>The role of Epstein-Barr virus in epithelial malignancies.</article-title>
            <source>J Pathol</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>235</volume>
            <issue>2</issue>
            <fpage>323</fpage>
            <page-range>323-33</page-range>
            <pub-id pub-id-type="pmid">25251730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawson</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Port</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC).</article-title>
            <source>Semin Cancer Biol</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-53</page-range>
            <pub-id pub-id-type="pmid">22249143</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raab-Traub</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Nasopharyngeal Carcinoma: An Evolving Role for the Epstein-Barr Virus.</article-title>
            <source>Curr Top Microbiol Immunol</source>
            <year>2015</year>
            <volume>390</volume>
            <issue>Pt 1</issue>
            <fpage>339</fpage>
            <page-range>339-63</page-range>
            <pub-id pub-id-type="pmid">26424653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shang</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lyu</surname>
                <given-names>XQ</given-names>
              </name>
            </person-group>
            <article-title>[Nasopharyngeal carcinoma with non-squamous immunophenotype: a clinicopathological analysis of 23 cases].</article-title>
            <source>Zhonghua Bing Li Xue Za Zhi</source>
            <year>2022</year>
            <month>Jun</month>
            <day>08</day>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>500</fpage>
            <page-range>500-505</page-range>
            <pub-id pub-id-type="pmid">35673720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rana</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Kumari</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinicopathological Challenges in Tumors of the Nasal Cavity and Paranasal Sinuses: Our Experience.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>9</issue>
            <fpage>e29128</fpage>
            <pub-id pub-id-type="pmid">36259025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhai</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical and Histopathologic Analyses of Nasopharyngeal Hyalinizing Clear Cell Carcinoma: A Series of 26 Cases With Molecular Confirmation.</article-title>
            <source>Am J Surg Pathol</source>
            <year>2023</year>
            <month>Oct</month>
            <day>01</day>
            <volume>47</volume>
            <issue>10</issue>
            <fpage>1168</fpage>
            <page-range>1168-1175</page-range>
            <pub-id pub-id-type="pmid">37377124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tay</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Siow</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>KS</given-names>
              </name>
            </person-group>
            <article-title>A comparison of EBV serology and serum cell-free DNA as screening tools for nasopharyngeal cancer: Results of the Singapore NPC screening cohort.</article-title>
            <source>Int J Cancer</source>
            <year>2020</year>
            <month>May</month>
            <day>15</day>
            <volume>146</volume>
            <issue>10</issue>
            <fpage>2923</fpage>
            <page-range>2923-2931</page-range>
            <pub-id pub-id-type="pmid">31705522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Majima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Maeda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirayama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Azuma</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>An Unusual Presentation of Nasopharyngeal Carcinoma as Lemierre Syndrome.</article-title>
            <source>Am J Case Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>28</day>
            <volume>20</volume>
            <fpage>263</fpage>
            <page-range>263-267</page-range>
            <pub-id pub-id-type="pmid">30814483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>al-Arayedh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rashid</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Nasopharynx: clinical, pathologic, and radiologic assessment.</article-title>
            <source>Neuroimaging Clin N Am</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>465</fpage>
            <page-range>465-83</page-range>
            <pub-id pub-id-type="pmid">14631685</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Imaging of nasopharyngeal carcinoma.</article-title>
            <source>Ann Acad Med Singap</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>809</fpage>
            <page-range>809-16</page-range>
            <pub-id pub-id-type="pmid">19816641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Metreweli</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Paranasopharyngeal space involvement in nasopharyngeal cancer: detection by CT and MRI.</article-title>
            <source>Clin Oncol (R Coll Radiol)</source>
            <year>2000</year>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>397</fpage>
            <page-range>397-402</page-range>
            <pub-id pub-id-type="pmid">11202093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Vlantis</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Tse</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Primary nasopharyngeal carcinoma: diagnostic accuracy of MR imaging versus that of endoscopy and endoscopic biopsy.</article-title>
            <source>Radiology</source>
            <year>2011</year>
            <month>Feb</month>
            <volume>258</volume>
            <issue>2</issue>
            <fpage>531</fpage>
            <page-range>531-7</page-range>
            <pub-id pub-id-type="pmid">21131580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic accuracy of diffusion-weighted MR imaging for nasopharyngeal carcinoma, head and neck lymphoma and squamous cell carcinoma at the primary site.</article-title>
            <source>Oral Oncol</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>8</issue>
            <fpage>603</fpage>
            <page-range>603-6</page-range>
            <pub-id pub-id-type="pmid">20619723</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lian</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ZJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>SG</given-names>
              </name>
            </person-group>
            <article-title>Biopsy of cervical lymph node does not impact the survival of nasopharyngeal carcinoma.</article-title>
            <source>Cancer Med</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>10</volume>
            <issue>19</issue>
            <fpage>6687</fpage>
            <page-range>6687-6696</page-range>
            <pub-id pub-id-type="pmid">34382376</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ye</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Compliance with National Guidelines on the Treatment of Stage II&#x02013;IVB Nasopharyngeal Carcinoma in a Regional Cancer Center of Southern China.</article-title>
            <source>Asian Pac J Cancer Prev</source>
            <year>2018</year>
            <month>Jan</month>
            <day>27</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>115</fpage>
            <page-range>115-120</page-range>
            <pub-id pub-id-type="pmid">29373901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Poh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>AlHussain</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Corry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gr&#x000e9;goire</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Langendijk</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>TX</given-names>
              </name>
              <name>
                <surname>Mendenhall</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ozyar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Soong</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yom</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.</article-title>
            <source>Radiother Oncol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-36</page-range>
            <pub-id pub-id-type="pmid">29153464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>WI</given-names>
              </name>
            </person-group>
            <article-title>Salvage surgery for nasopharyngeal cancer.</article-title>
            <source>World J Otorhinolaryngol Head Neck Surg</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-43</page-range>
            <pub-id pub-id-type="pmid">29204538</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsang</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>Treatment of persistent/recurrent nodal disease in nasopharyngeal cancer.</article-title>
            <source>Curr Opin Otolaryngol Head Neck Surg</source>
            <year>2021</year>
            <month>Apr</month>
            <day>01</day>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>86</fpage>
            <page-range>86-92</page-range>
            <pub-id pub-id-type="pmid">33278136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chiang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Poh</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>AlHussain</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Corry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Grau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gr&#x000e9;goire</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Langendijk</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>TX</given-names>
              </name>
              <name>
                <surname>Mendenhall</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ozyar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Sanguineti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Soong</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yom</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>567</fpage>
            <page-range>567-580</page-range>
            <pub-id pub-id-type="pmid">31276776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Pathologic study of tumour extension for clinically localized unilateral nasopharyngeal carcinoma: Should the contralateral side be included in the clinical target volume?</article-title>
            <source>J Med Imaging Radiat Oncol</source>
            <year>2018</year>
            <month>May</month>
            <day>28</day>
            <pub-id pub-id-type="pmid">29808625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Tao</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reduction of clinical target volume in patients with lateralized cancer of the nasopharynx and without contralateral lymph node metastasis receiving intensity-modulated radiotherapy.</article-title>
            <source>Head Neck</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>38 Suppl 1</volume>
            <fpage>E468</fpage>
            <page-range>E468-72</page-range>
            <pub-id pub-id-type="pmid">25677692</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanford</surname>
                <given-names>NN</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lam</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Juliano</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Liebsch</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Curtin</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AW</given-names>
              </name>
            </person-group>
            <article-title>Individualization of Clinical Target Volume Delineation Based on Stepwise Spread of Nasopharyngeal Carcinoma: Outcome of More Than a Decade of Clinical Experience.</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>103</volume>
            <issue>3</issue>
            <fpage>654</fpage>
            <page-range>654-668</page-range>
            <pub-id pub-id-type="pmid">30712708</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>JCH</given-names>
              </name>
              <name>
                <surname>Beitler</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Corry</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mendenhall</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AWM</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Nuyts</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saba</surname>
                <given-names>NF</given-names>
              </name>
              <name>
                <surname>Smee</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stokes</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Strojan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ferlito</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Current Radiotherapy Considerations for Nasopharyngeal Carcinoma.</article-title>
            <source>Cancers (Basel)</source>
            <year>2022</year>
            <month>Nov</month>
            <day>24</day>
            <volume>14</volume>
            <issue>23</issue>
            <pub-id pub-id-type="pmid">36497254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ho</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Tham</surname>
                <given-names>IW</given-names>
              </name>
              <name>
                <surname>Earnest</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence.</article-title>
            <source>BMC Cancer</source>
            <year>2012</year>
            <month>Mar</month>
            <day>21</day>
            <volume>12</volume>
            <fpage>98</fpage>
            <pub-id pub-id-type="pmid">22433671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Neck level Ib-sparing versus level Ib-irradiation in intensity-modulated radiotherapy for the treatment of nasopharyngeal carcinoma with high-risk factors: A propensity score-matched cohort study.</article-title>
            <source>Radiother Oncol</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>177</volume>
            <fpage>205</fpage>
            <page-range>205-213</page-range>
            <pub-id pub-id-type="pmid">36375564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Patterns of local-regional failure after primary intensity modulated radiotherapy for nasopharyngeal carcinoma.</article-title>
            <source>Radiat Oncol</source>
            <year>2014</year>
            <month>Feb</month>
            <day>19</day>
            <volume>9</volume>
            <fpage>60</fpage>
            <pub-id pub-id-type="pmid">24552293</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fontanarosa</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Variations of Clinical Target Volume Delineation for Primary Site of Nasopharyngeal Cancer Among Five Centers in China.</article-title>
            <source>Front Oncol</source>
            <year>2020</year>
            <volume>10</volume>
            <fpage>1572</fpage>
            <pub-id pub-id-type="pmid">32974193</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buehrlen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zwaan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Granzen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lassay</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deutz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vorwerk</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Staatz</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gademann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Oldenburger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tamm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mertens</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: preliminary results from the prospective, multicenter study NPC-2003-GPOH/DCOG.</article-title>
            <source>Cancer</source>
            <year>2012</year>
            <month>Oct</month>
            <day>01</day>
            <volume>118</volume>
            <issue>19</issue>
            <fpage>4892</fpage>
            <page-range>4892-900</page-range>
            <pub-id pub-id-type="pmid">22359313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Young</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thwaites</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Holloway</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Assessment of electron density effects on dose calculation and optimisation accuracy for nasopharynx, for MRI only treatment planning.</article-title>
            <source>Australas Phys Eng Sci Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>41</volume>
            <issue>4</issue>
            <fpage>811</fpage>
            <page-range>811-820</page-range>
            <pub-id pub-id-type="pmid">30120757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bouaouina</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ouni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kanoun</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Neffeti</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Kermani</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Abdelkefi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Metastatic nasopharynx cancer at diagnosis: clinical and prognostic (study of 51 cases)].</article-title>
            <source>Pan Afr Med J</source>
            <year>2018</year>
            <volume>29</volume>
            <fpage>155</fpage>
            <pub-id pub-id-type="pmid">30050619</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Rudra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oppelt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adkins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rich</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Zevallos</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gay</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Thorstad</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Induction chemotherapy in the treatment of nasopharyngeal carcinoma: Clinical outcomes and patterns of care.</article-title>
            <source>Cancer Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>8</issue>
            <fpage>3592</fpage>
            <page-range>3592-3603</page-range>
            <pub-id pub-id-type="pmid">30008178</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Ismaila</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>MLK</given-names>
              </name>
              <name>
                <surname>Colevas</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Wee</surname>
                <given-names>JTS</given-names>
              </name>
              <name>
                <surname>Whitley</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Yi</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Yom</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>ATC</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>QT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AWM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2021</year>
            <month>Mar</month>
            <day>01</day>
            <volume>39</volume>
            <issue>7</issue>
            <fpage>840</fpage>
            <page-range>840-859</page-range>
            <pub-id pub-id-type="pmid">33405943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Sarraf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LeBlanc</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giri</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vuong</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Forastiere</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sakr</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Ensley</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.</article-title>
            <source>J Clin Oncol</source>
            <year>1998</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>1310</fpage>
            <page-range>1310-7</page-range>
            <pub-id pub-id-type="pmid">9552031</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Ngan</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Mok</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>FK</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma.</article-title>
            <source>J Natl Cancer Inst</source>
            <year>2005</year>
            <month>Apr</month>
            <day>06</day>
            <volume>97</volume>
            <issue>7</issue>
            <fpage>536</fpage>
            <page-range>536-9</page-range>
            <pub-id pub-id-type="pmid">15812080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Tai</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Loong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sethi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Machin</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Sep</month>
            <day>20</day>
            <volume>23</volume>
            <issue>27</issue>
            <fpage>6730</fpage>
            <page-range>6730-8</page-range>
            <pub-id pub-id-type="pmid">16170180</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Zong</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China.</article-title>
            <source>Cancer</source>
            <year>2013</year>
            <month>Jun</month>
            <day>15</day>
            <volume>119</volume>
            <issue>12</issue>
            <fpage>2230</fpage>
            <page-range>2230-8</page-range>
            <pub-id pub-id-type="pmid">23576020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>AWM</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ngan</surname>
                <given-names>RKC</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HCW</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>LLK</given-names>
              </name>
              <name>
                <surname>Siu</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>AWY</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>HHY</given-names>
              </name>
              <name>
                <surname>O'Sullivan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chappell</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity.</article-title>
            <source>Cancer</source>
            <year>2017</year>
            <month>Nov</month>
            <day>01</day>
            <volume>123</volume>
            <issue>21</issue>
            <fpage>4147</fpage>
            <page-range>4147-4157</page-range>
            <pub-id pub-id-type="pmid">28662313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwong</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Sham</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Chua</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Kwok</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Choy</surname>
                <given-names>DD</given-names>
              </name>
            </person-group>
            <article-title>Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>Jul</month>
            <day>01</day>
            <volume>22</volume>
            <issue>13</issue>
            <fpage>2643</fpage>
            <page-range>2643-53</page-range>
            <pub-id pub-id-type="pmid">15226332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hui</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kam</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Zee</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <day>10</day>
            <volume>27</volume>
            <issue>2</issue>
            <fpage>242</fpage>
            <page-range>242-9</page-range>
            <pub-id pub-id-type="pmid">19064973</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Ngan</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>TX</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Yau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>OS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chappell</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma.</article-title>
            <source>Cancer</source>
            <year>2015</year>
            <month>Apr</month>
            <day>15</day>
            <volume>121</volume>
            <issue>8</issue>
            <fpage>1328</fpage>
            <page-range>1328-38</page-range>
            <pub-id pub-id-type="pmid">25529384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cao</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>ZX</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>LQ</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.</article-title>
            <source>Eur J Cancer</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>75</volume>
            <fpage>14</fpage>
            <page-range>14-23</page-range>
            <pub-id pub-id-type="pmid">28214653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ZQ</given-names>
              </name>
              <name>
                <surname>Mai</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>LQ</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Qian</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>YQ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>ZX</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.</article-title>
            <source>Eur J Cancer</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>119</volume>
            <fpage>87</fpage>
            <page-range>87-96</page-range>
            <pub-id pub-id-type="pmid">31425966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r78">
          <label>78</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>AWM</given-names>
              </name>
              <name>
                <surname>Ngan</surname>
                <given-names>RKC</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>AAC</given-names>
              </name>
              <name>
                <surname>Kwong</surname>
                <given-names>DLW</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>TX</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>ATC</given-names>
              </name>
              <name>
                <surname>Sze</surname>
                <given-names>HCK</given-names>
              </name>
              <name>
                <surname>Yiu</surname>
                <given-names>HHY</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>FCS</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Chappell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HCW</given-names>
              </name>
            </person-group>
            <article-title>NPC-0501 trial on the value of changing chemoradiotherapy sequence, replacing 5-fluorouracil with capecitabine, and altering fractionation for patients with advanced nasopharyngeal carcinoma.</article-title>
            <source>Cancer</source>
            <year>2020</year>
            <month>Aug</month>
            <day>15</day>
            <volume>126</volume>
            <issue>16</issue>
            <fpage>3674</fpage>
            <page-range>3674-3688</page-range>
            <pub-id pub-id-type="pmid">32497261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r79">
          <label>79</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>XZ</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>ZB</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Xie</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>GX</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Tang</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>MZ</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>163</fpage>
            <page-range>163-71</page-range>
            <pub-id pub-id-type="pmid">22154591</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r80">
          <label>80</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chitapanarux</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kittichest</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tungkasamit</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asakit</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chomprasert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chakrabandhu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Onchan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Traisathit</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Two-year outcome of concurrent chemoradiation with carboplatin with or without adjuvant carboplatin/fluorouracil in nasopharyngeal cancer: A multicenter randomized trial.</article-title>
            <source>Curr Probl Cancer</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>100620</fpage>
            <pub-id pub-id-type="pmid">32713518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r81">
          <label>81</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Developing a nomogram model and prognostic analysis of nasopharyngeal squamous cell carcinoma patients: a population-based study.</article-title>
            <source>J Cancer Res Clin Oncol</source>
            <year>2023</year>
            <month>Oct</month>
            <volume>149</volume>
            <issue>13</issue>
            <fpage>12165</fpage>
            <page-range>12165-12175</page-range>
            <pub-id pub-id-type="pmid">37428250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r82">
          <label>82</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Mo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Prognostic nomograms for nasopharyngeal carcinoma with nodal features and potential indication for N staging system: Validation and comparison of seven N stage schemes.</article-title>
            <source>Oral Oncol</source>
            <year>2023</year>
            <month>Sep</month>
            <volume>144</volume>
            <fpage>106438</fpage>
            <pub-id pub-id-type="pmid">37437499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r83">
          <label>83</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alami</surname>
                <given-names>IE</given-names>
              </name>
              <name>
                <surname>Gihbid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Charoute</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khaali</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Brahim</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Tawfiq</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cadi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Belghmi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>El Mzibri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khyatti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis.</article-title>
            <source>Pan Afr Med J</source>
            <year>2022</year>
            <volume>41</volume>
            <fpage>6</fpage>
            <pub-id pub-id-type="pmid">35145598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r84">
          <label>84</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mao</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Wen</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Kou</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>XL</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>GQ</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Liquid biopsy posttreatment surveillance in endemic nasopharyngeal carcinoma: a cost-effective strategy to integrate circulating cell-free Epstein-Barr virus DNA.</article-title>
            <source>BMC Med</source>
            <year>2021</year>
            <month>Aug</month>
            <day>26</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>193</fpage>
            <pub-id pub-id-type="pmid">34433440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r85">
          <label>85</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thamboo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Shoucair</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jabarin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Prisman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Garnis</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Surveillance tools for detection of recurrent nasopharyngeal carcinoma: An evidence-based review and recommendations.</article-title>
            <source>World J Otorhinolaryngol Head Neck Surg</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-204</page-range>
            <pub-id pub-id-type="pmid">36159905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r86">
          <label>86</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Comparison of 18F-FDG PET/CT, MRI and SPECT in the diagnosis of local residual/recurrent nasopharyngeal carcinoma: A meta-analysis.</article-title>
            <source>Oral Oncol</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>52</volume>
            <fpage>11</fpage>
            <page-range>11-7</page-range>
            <pub-id pub-id-type="pmid">26547126</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r87">
          <label>87</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ng</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YC</given-names>
              </name>
            </person-group>
            <article-title>Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.</article-title>
            <source>Eur Radiol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>20</volume>
            <issue>9</issue>
            <fpage>2229</fpage>
            <page-range>2229-40</page-range>
            <pub-id pub-id-type="pmid">20393714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25574.r88">
          <label>88</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>FDG-PET, CT, MRI for diagnosis of local residual or recurrent nasopharyngeal carcinoma, which one is the best? A systematic review.</article-title>
            <source>Radiother Oncol</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>327</fpage>
            <page-range>327-35</page-range>
            <pub-id pub-id-type="pmid">18037523</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
